191 related articles for article (PubMed ID: 15220824)
1. Pharmacogenomics.
Ross JS; Schenkein DP; Kashala O; Linette GP; Stec J; Symmans WF; Pusztai L; Hortobagyi GN
Adv Anat Pathol; 2004 Jul; 11(4):211-20. PubMed ID: 15220824
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics and clinical biomarkers in drug discovery and development.
Ross JS; Symmans WF; Pusztai L; Hortobagyi GN
Am J Clin Pathol; 2005 Dec; 124 Suppl():S29-41. PubMed ID: 16468416
[TBL] [Abstract][Full Text] [Related]
3. Gene expression-driven diagnostics and pharmacogenomics in cancer.
Wang Y
Curr Opin Mol Ther; 2005 Jun; 7(3):246-50. PubMed ID: 15977422
[TBL] [Abstract][Full Text] [Related]
4. Personalized pharmacogenomics profiling using whole-genome sequencing.
Mizzi C; Peters B; Mitropoulou C; Mitropoulos K; Katsila T; Agarwal MR; van Schaik RH; Drmanac R; Borg J; Patrinos GP
Pharmacogenomics; 2014 Jun; 15(9):1223-34. PubMed ID: 25141897
[TBL] [Abstract][Full Text] [Related]
5. [Polygenetic pharmacogenomic strategies to identify drug sensitivity biomarkers].
Nishiyama M
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1902-7. PubMed ID: 16282724
[TBL] [Abstract][Full Text] [Related]
6. The Use of DNA Microarrays to Investigate the Pharmacogenomics of Drug Response in Living Systems.
Villeneuve DJ; Parissenti AM
Curr Top Med Chem; 2004; 4(13):1327-1343. PubMed ID: 15379648
[TBL] [Abstract][Full Text] [Related]
7. Evolution of pharmacogenomics.
Somogy A
Proc West Pharmacol Soc; 2008; 51():1-4. PubMed ID: 19544663
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics in breast cancer: current trends and future directions.
Wajapeyee N; Somasundaram K
Curr Opin Mol Ther; 2004 Jun; 6(3):296-301. PubMed ID: 15264432
[TBL] [Abstract][Full Text] [Related]
9. Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity.
Auman JT; McLeod HL
Drug Metab Rev; 2008; 40(2):303-15. PubMed ID: 18464047
[TBL] [Abstract][Full Text] [Related]
10. Microarrays in pharmacogenomics--advances and future promise.
Chicurel ME; Dalma-Weiszhausz DD
Pharmacogenomics; 2002 Sep; 3(5):589-601. PubMed ID: 12223046
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics and its potential impact on drug and formulation development.
Regnstrom K; Burgess DJ
Crit Rev Ther Drug Carrier Syst; 2005; 22(5):465-92. PubMed ID: 16313234
[TBL] [Abstract][Full Text] [Related]
12. Personalised medicine for cancer: from drug development into clinical practice.
Jain KK
Expert Opin Pharmacother; 2005 Aug; 6(9):1463-76. PubMed ID: 16086635
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.
Rushmore TH; Kong AN
Curr Drug Metab; 2002 Oct; 3(5):481-90. PubMed ID: 12369894
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy.
Mango R; Vecchione L; Raso B; Borgiani P; Brunetti E; Mehta JL; Lauro R; Romeo F; Novelli G
Expert Opin Pharmacother; 2005 Dec; 6(15):2565-76. PubMed ID: 16316297
[TBL] [Abstract][Full Text] [Related]
15. DMET microarray technology for pharmacogenomics-based personalized medicine.
Burmester JK; Sedova M; Shapero MH; Mansfield E
Methods Mol Biol; 2010; 632():99-124. PubMed ID: 20217574
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics and pharmacogenomics as new tools to optimise cancer chemotherapy.
Robert J
J Chemother; 2004 Nov; 16 Suppl 4():22-4. PubMed ID: 15688604
[TBL] [Abstract][Full Text] [Related]
17. Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020.
Huang RS; Dolan ME
Pharmacogenomics; 2010 Apr; 11(4):471-4. PubMed ID: 20350124
[TBL] [Abstract][Full Text] [Related]
18. Progress towards the integration of pharmacogenomics in practice.
Mooney SD
Hum Genet; 2015 May; 134(5):459-65. PubMed ID: 25238897
[TBL] [Abstract][Full Text] [Related]
19. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer.
Sauna ZE; Kimchi-Sarfaty C; Ambudkar SV; Gottesman MM
Cancer Res; 2007 Oct; 67(20):9609-12. PubMed ID: 17942888
[TBL] [Abstract][Full Text] [Related]
20. Molecular staging and pharmacogenomics. Clinical implications: from lab to patients and back.
Franklin WA; Carbone DP
Lung Cancer; 2003 Aug; 41 Suppl 1():S147-54. PubMed ID: 12867073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
